Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Cost of Revenue (2016 - 2025)

China Pharma Holdings filings provide 16 years of Cost of Revenue readings, the most recent being $4.0 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 185.47% to $4.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $5.5 million, a 932.75% increase, with the full-year FY2025 number at $4.3 million, up 708.63% from a year prior.
  • Cost of Revenue hit $4.0 million in Q4 2025 for China Pharma Holdings, up from $78041.0 in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $4.0 million in Q4 2025 to a low of -$4.7 million in Q4 2024.
  • Median Cost of Revenue over the past 5 years was $457618.5 (2021), compared with a mean of $525445.0.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 892.62% in 2023 and later crashed 1907.41% in 2024.
  • China Pharma Holdings' Cost of Revenue stood at $536902.0 in 2021, then plummeted by 966.06% to -$4.6 million in 2022, then surged by 105.58% to $259552.0 in 2023, then crashed by 1907.41% to -$4.7 million in 2024, then soared by 185.47% to $4.0 million in 2025.
  • The last three reported values for Cost of Revenue were $4.0 million (Q4 2025), $78041.0 (Q3 2025), and $101292.0 (Q2 2025) per Business Quant data.